Evidence‑Based Recommendations for Corticosteroid Therapy

Systemic Corticosteroids – Classification & Potency

• Hydrocortisone has short‑acting, low potency (baseline 1×); prednisolone/methylprednisolone are intermediate‑acting with 4–5 × the potency of hydrocortisone; dexamethasone is long‑acting with ≈ 25 × the potency of hydrocortisone【1】.

Systemic Corticosteroids – Asthma Exacerbation Dosing

• For acute asthma exacerbations, prescribe oral prednisolone 1–2 mg kg⁻¹ day⁻¹ in two divided doses (maximum 60 mg day⁻¹) until forced expiratory volume reaches ≥ 70 % of predicted【2】.
• No clinical advantage of intravenous over oral administration when gastrointestinal absorption is intact【2】.
• Short courses of 3–10 days do not require tapering, especially when the patient is already using inhaled corticosteroids【2】.

Systemic Corticosteroids – Specific Indications (non‑Praxis sources)

• Dexamethasone is indicated for conditions requiring intense anti‑inflammatory suppression, such as elevated intracranial pressure and malignant bowel obstruction【3】.
• Systemic corticosteroids are recommended for refractory ulcerative colitis when optimized 5‑ASA therapy fails, using oral prednisolone or budesonide MMX【4】.

Systemic Corticosteroids – Adverse Effects & Cardiovascular Risk

• Common adverse effects include hypothalamic‑pituitary‑adrenal axis suppression, growth inhibition, skin thinning, hypertension, diabetes, Cushing‑like features, cataracts, muscle weakness, and immune dysfunction【1】.
• Current users have an odds ratio of 2.7 for atrial fibrillation; high‑dose therapy (≥ 7.5 mg prednisolone‑equivalent) raises the odds ratio to 6.07【1】.

Topical Corticosteroids – Classification by Potency

• Topical corticosteroids are grouped into seven classes based on cutaneous vasoconstriction; Class 1 is ultra‑high potency, Classes 6–7 are low potency【5】.

Ultra‑High Potency (Class 1)

• Clobetasol propionate 0.05 % and halobetasol propionate 0.05 % are the agents of choice for thick, chronic plaques on trunk and extremities【1】.
• Clinical efficacy ranges from 58 % to 92 %【5】.
• Limit continuous use to 2–4 weeks (maximum 50 g week⁻¹); avoid application on the face or intertriginous areas, as all users developed atrophy after 8 weeks in studies【5】.

High Potency (Class 2)

• Amcinonide 0.1 %, betamethasone dipropionate 0.05 %, and fluocinonide 0.05 % are effective for plaque psoriasis, with reported efficacy of 68 %–74 % when used for up to 4 weeks【5】.

Medium Potency (Classes 3–4)

• Fluticasone propionate 0.005 % ointment (Class 3) and betamethasone valerate foam (Class 4) show efficacy of 68 %–72 % and may be continued for up to 12 weeks under careful supervision【5】.
• Only 2 cases of skin atrophy were reported among 2,266 participants using Class 4 agents【5】.

Low Potency (Classes 5–7) – Dermatology Society Recommendation

• Hydrocortisone 2.5 % is recommended by the American Academy of Dermatology for facial use【6】.
• Desonide 0.05 % and alclometasone 0.05 % are acceptable low‑potency alternatives【6】.
• Overall efficacy of low‑potency agents ranges from 41 % to 83 %【5】.
• Minimal risk of skin atrophy (≈ 1 % of users) has been observed with low‑potency preparations【6】.

Anatomical Site‑Specific Selection

• Face, genitalia, and intertriginous zones: use only Classes 5–7 (low potency) to minimize systemic absorption and atrophy【5】.
• Trunk and extremities with thick, chronic plaques: consider Classes 1–3 (ultra‑high to medium potency)【5】.
• Scalp: any potency class may be used for up to 4 weeks【5】.
• Palms and soles: high to ultra‑high potency (Classes 1–2) is required because of the thick stratum corneum【5】.

Special Populations

• Older adults: preferentially prescribe low‑potency (Classes 6–7) agents on the face, neck, and intertriginous areas to reduce steroid‑induced atrophy【5】.
• Children: select lower‑potency agents and shorter treatment courses; Class 6 agents carry a lower risk of adrenal suppression compared with higher‑potency steroids【5】; prolonged use may impair growth【5】.

Combination Therapy for Psoriasis

• Combining vitamin D analogues with potent topical corticosteroids yields superior outcomes compared with monotherapy, achieving clear or almost clear skin in 69 %–74 % of patients after 52 weeks without serious adverse events【5】.

Tachyphylaxis Myth

• A prospective 12‑week study found no evidence of true glucocorticoid‑receptor down‑regulation (true tachyphylaxis) with continuous topical steroid use; apparent loss of response is more likely due to poor patient adherence【5】.
• When response is inadequate, the recommended strategy is to increase steroid potency or improve adherence rather than switch to a lower‑potency agent【5】.

Inhaled Corticosteroids – Initiation Timing

• Inhaled corticosteroids may be initiated at any point during an asthma exacerbation【2】.